Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

NCT04126070 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Hormone Sensitive Prostate Cancer
Prostate Adenocarcinoma
Metastasis Prostate Adenocarcinoma

Interventions

DRUG: Androgen Deprivation Therapy
DRUG: Nivolumab
DRUG: Docetaxel

Sponsor

Xiao X. Wei, MD

Collaborators

[object Object]